Here are the S-3 shelf registrations from Equillium, Inc. (EQ) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow EQ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EQ filings page.
Equillium, Inc. (EQ) seeks to register for resale by selling stockholders up to 35,087,717 shares of common stock, including 20,130,457 shares issuable upon exercise of pre-funded warrants. The selling stockholders may not sell until the registration statement is effective. Equillium is not selling shares and will receive no proceeds from resales; it would receive the $0.0001-per-share exercise price if holders exercise the warrants for cash.
At the milestone closing on October 26, 2026, Equillium sold and issued 14,957,260 common shares and warrants to purchase 20,130,457 shares. The purchase price at that closing was approximately $20.0 million, and gross proceeds across the initial and milestone closings were approximately $50.0 million.
Equillium, Inc. is registering 18,878,101 shares of common stock for resale by a selling stockholder. The registration covers 1,179,508 shares sold in a private placement and a pre-funded warrant exercisable for 17,698,593 shares. We will receive no proceeds from resales under this prospectus.
The private placement closed March 13, 2026 for approximately $35.0 million; the pre-funded warrant has a per-share exercise price of $0.0001 and includes a specified beneficial ownership limitation. Shares may be sold in various ways including block trades, market transactions or through underwriters; the selling stockholder listed is RA Capital Healthcare Fund, L.P..